Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pexidartinib hydrochloride

View Patient Information
The hydrochloride salt form of pexidartinib, a small-molecule receptor tyrosine kinase (RTK) inhibitor of proto-oncogene receptor tyrosine kinase (KIT), colony-stimulating factor-1 receptor (CSF1R) and FMS-like tyrosine kinase 3 (FLT3), with antineoplastic activity. Upon oral administration, pexidartinib targets, binds to and inhibits phosphorylation of KIT, CSF1R and FLT3 harboring an internal tandem duplication (ITD) mutation. This results in the inhibition of tumor cell proliferation. FLT3, CSF1R and FLT3 are overexpressed or mutated in many cancer cell types and play major roles in tumor cell proliferation and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:PLX3397 HCl
PLX3397 hydrochloride
US brand name:Turalio
Chemical structure:(5-(5-chloro-1H-pyrrolo(2,3-b)pyridin-3-ylmethyl)-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride salt
5[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)pyridin-3yl]methyl}pyridin-2-amine monohydrochloride
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search